Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin J Filipski

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry Letters|April 9, 2013
The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitusAngel Guzman-Perez, Jeffrey A Pfefferkorn, Esther C Y Lee, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Chemical Probe Identification Platform for Orphan GPCRs Using Focused Compound Screening: GPR39 as a Case ExampleMarkus Boehm, David Hepworth, Paula M Loria, et al.
The Journal of Biological Chemistry|November 15, 2025
Discovery of small molecule modulators of the thin filament that alter the contractile profile in a hypertrophic cardiomyopathy engineered tissue modelRuth F Sommese, Samuel M Levi, Janice Brown, et al.
Chemical Biology & Drug Design|June 22, 2007
Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitorsChad A Van Huis, Christopher F Bigge, Agustin Casimiro-Garcia, et al.
Bioorganic & Medicinal Chemistry Letters|August 30, 2005
The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complexJeffrey T Kohrt, Kevin J Filipski, Wayne L Cody, et al.
Bioorganic & Medicinal Chemistry|March 15, 2006
The discovery of glycine and related amino acid-based factor Xa inhibitorsJeffrey T Kohrt, Kevin J Filipski, Wayne L Cody, et al.
Chemical Biology & Drug Design|August 9, 2007
The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitorJeffrey T Kohrt, Christopher F Bigge, John W Bryant, et al.
Molecular Metabolism|October 11, 2022
BDK inhibition acts as a catabolic switch to mimic fasting and improve metabolism in miceEliza Bollinger, Matthew Peloquin, Jenna Libera, et al.
Bioorganic & Medicinal Chemistry Letters|July 9, 2013
Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motifKevin J Filipski, Angel Guzman-Perez, Jianwei Bian, et al.
Bioorganic & Medicinal Chemistry Letters|October 24, 2012
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitusJeffrey A Pfefferkorn, Meihua Tu, Kevin J Filipski, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|April 9, 2013
The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitusAngel Guzman-Perez, Jeffrey A Pfefferkorn, Esther C Y Lee, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Chemical Probe Identification Platform for Orphan GPCRs Using Focused Compound Screening: GPR39 as a Case ExampleMarkus Boehm, David Hepworth, Paula M Loria, et al.
The Journal of Biological Chemistry|November 15, 2025
Discovery of small molecule modulators of the thin filament that alter the contractile profile in a hypertrophic cardiomyopathy engineered tissue modelRuth F Sommese, Samuel M Levi, Janice Brown, et al.
Chemical Biology & Drug Design|June 22, 2007
Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitorsChad A Van Huis, Christopher F Bigge, Agustin Casimiro-Garcia, et al.
Bioorganic & Medicinal Chemistry Letters|August 30, 2005
The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complexJeffrey T Kohrt, Kevin J Filipski, Wayne L Cody, et al.
Bioorganic & Medicinal Chemistry|March 15, 2006
The discovery of glycine and related amino acid-based factor Xa inhibitorsJeffrey T Kohrt, Kevin J Filipski, Wayne L Cody, et al.
Chemical Biology & Drug Design|August 9, 2007
The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitorJeffrey T Kohrt, Christopher F Bigge, John W Bryant, et al.
Molecular Metabolism|October 11, 2022
BDK inhibition acts as a catabolic switch to mimic fasting and improve metabolism in miceEliza Bollinger, Matthew Peloquin, Jenna Libera, et al.
Bioorganic & Medicinal Chemistry Letters|July 9, 2013
Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motifKevin J Filipski, Angel Guzman-Perez, Jianwei Bian, et al.
Bioorganic & Medicinal Chemistry Letters|October 24, 2012
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitusJeffrey A Pfefferkorn, Meihua Tu, Kevin J Filipski, et al.
Pageof 4